km.idaeo.ai · IDAEO 知識庫

🏛 Part of the "health" topic shelf

How Should Diagnostic Imaging Be Chosen? An Evidence-Based Reading of LDCT, X-ray, PET/CT, MRI, and Gadolinium-Based Contrast Agents

The benefits and risks of medical imaging must be weighed together in the context of the indication, the examinee's risk profile, the imaging protocol, and the actions that will follow. LDCT provides a mortality benefit for people at high risk of lung cancer who meet eligibility criteria, but this does not justify population-wide screening. X-ray and CT involve ionizing radiation; MRI does not, although it still has limitations on when and how it can be used. Tissue retention of gadolinium-based contrast agents has been confirmed, but clinical neurologic harm has not. Drawing on Professor Ching-Shun Lin's original article and literature indexed by ECU, this article explains how to avoid mistaking “a test can be performed” for “a test should be performed,” while using the evolution of science to provide today's more precise account of risk.

Benefits, Limitations, and Risks of Diagnostic Imaging

Bottom line

Diagnostic imaging is not a binary choice between “radiation is dangerous” and “earlier detection must be beneficial.” The examination most likely to change treatment, with overall benefits exceeding harms, should be selected according to the individual's risk, the clinical objective, the imaging protocol, and the actions that will follow. PMID: 33687470

LDCT: Effective screening for high-risk groups does not mean population-wide screening is beneficial

Professor Ching-Shun Lin's original article opposed marketing low-dose computed tomography to all women over age forty. Its point was not to reject LDCT, but to reject the omission of risk stratification. Randomized trials show that LDCT can reduce lung-cancer mortality among high-risk smokers. The same trial also found that a large proportion of positive results were false positives, exposing examinees to follow-up imaging, invasive procedures, and anxiety. Benefit and harm therefore coexist; campaigns cannot promote only “early detection.” PMID: 21714641

An ecological cohort study of lung cancer among Taiwanese women found that, during the expansion of LDCT, the incidence of early-stage lung cancer increased more than sixfold, while the incidence of late-stage disease and mortality did not decline in parallel. This supports Professor Lin's warning about substantial overdiagnosis: some cancers detected might never cause symptoms or premature death during a person's lifetime. Such research, however, cannot determine how an individual patient's tumor will progress and cannot be used to tell a patient to forgo necessary treatment on their own. PMID: 35040922

Overdiagnosis is not an abstract concept but a real harm that must be explained before informed decisions about lung-cancer screening are made. Current guidelines restrict LDCT eligibility to high-risk people who meet age and smoking-exposure criteria, further demonstrating that benefits established in trials of high-risk groups cannot be directly extrapolated to adults in general. PMID: 24322569 PMID: 33687470

X-ray and CT: Optimize dose without calling low risk zero risk

CT uses ionizing radiation. Repeated exposure, or exposure without clinical necessity, must therefore be considered in relation to the risk of radiation-induced cancer. A reasonable approach is first to determine whether the examination will change diagnosis or management, and then use a protocol sufficient to answer the clinical question—not to reject all necessary imaging out of fear. PMID: 42438930

Professor Lin's original article cited the understanding at the time that epidemiologic evidence remained inconclusive for diagnostic exposures below one hundred millisieverts. With the literature now updated, a more precise formulation is that cumulative low-dose exposure may contribute to long-term risk, but the risk to any individual remains difficult to quantify accurately because of dose-estimation uncertainty and confounding. “Inconclusive” should therefore not be read as “entirely risk-free,” nor does it mean that the benefit of appropriate medical imaging is overturned by a very small and uncertain risk. PMID: 41977229 PMID: 39021204

For mammography, current research has not found an increase in peripheral-blood circulating tumor cells after compression. Another study likewise found no clinically meaningful overall increase in circulating tumor DNA or tumor cells. These findings support the procedure's safety at the biomarker level, but the size and endpoints of the studies are insufficient, on their own, to prove that there is absolutely no risk of dissemination under any circumstances. PMID: 23990353 PMID: 31236809

Thyroid exposure from mammography is very low, and routine thyroid shielding is unnecessary; a shield may instead interfere with imaging and increase the need for repeat examinations. For dental X-rays, observational studies have not established causality, although associations with repeated exposure have been reported and are limited by recall bias and insufficient dose data. Radiation-protection judgments in dentistry cannot be directly transferred from conclusions about mammography. PMID: 22358013 PMID: 31502516 PMID: 32557182

PET/CT and MRI: Function, structure, and safety cannot be reduced to a slogan

PET can provide functional and metabolic information, but a blanket claim that CT or MRI can show only structure no longer adequately describes the capabilities of multimodal imaging and advanced MRI. Imaging choices should return to the clinical question the physician genuinely needs to answer, rather than rank modalities by a single technological label. PMID: 42254367

The radiation dose from PET/CT is not a fixed value. Professor Lin's original article discussed a video's claim of twenty-five millisieverts. More recent real-world data indicate that the average for standard protocols may be lower, while more complex whole-body imaging workflows may approach or exceed that value. Twenty-five millisieverts should therefore not be treated as the fixed, typical dose for every PET/CT examination. PMID: 41961220 PMID: 41996412

MRI does not use ionizing radiation and can be an alternative in suitable clinical circumstances. Yet “no ionizing radiation” does not mean that every patient, every implant, and every examination purpose is free of other safety constraints or limitations of applicability. PMID: 41973695

Gadolinium-based contrast agents: Confirmed retention is not the same as proven harm

Professor Lin's original article distinguished two matters that are often conflated. Gadolinium-based contrast agents can be retained in the brain or other tissues, and this may be observed even when kidney function is normal; however, resulting clinical neurologic harm has not been established. Reviews continue to support this distinction. News that “residue remains” should not be taken directly to mean that it “must cause disease.” PMID: 28361260 PMID: 37665796

Nephrogenic systemic fibrosis is associated primarily with severe kidney dysfunction, but risk is not identical across gadolinium-based agents, and modern data concerning lower-risk agents also differ. In practice, the healthcare team should know the patient's kidney function, the necessity of the examination, and the type of agent being considered, rather than treating all gadolinium-based contrast agents as carrying the same risk. PMID: 32976265 PMID: 34997298

Scientific progress has also made safety assessment more nuanced. The earlier reassurance that “no problem other than nephrogenic systemic fibrosis has been established” should now be qualified: the absence of proven clinical harm does not eliminate the need to consider agent stability, tissue retention, and the minimum necessary use. This is the language of risk management after the literature has been updated, not a rewriting of the position Professor Lin expressed at the time. PMID: 41069292 PMID: 40574249

Shielding and special populations: One rule cannot cover every examination

In modern projection radiography, routine contact shielding of patients usually offers little benefit. If positioned inaccurately, a shield may obscure anatomical information, cause repeat imaging, or interfere with automatic exposure control and increase the dose to the examined area. Nevertheless, high-quality comparative evidence remains limited for different examination types and for circumstances involving pregnant women, children, and other groups. “Routine shielding is no longer recommended in most cases” cannot be turned into “individual assessment is never needed under any circumstances.” PMID: 40965682 PMID: 22695996

For gonadal or fetal exposure, doses from modern diagnostic imaging are usually very low, and existing data have not conclusively demonstrated a risk of fetal cancer. Human data at low doses are limited, however, so assessment should still account for the stage of pregnancy and type of examination, avoiding absolute claims that harm is “completely impossible.” PMID: 28418814 PMID: 15191441

Reports must also be read in context: LSV in preterm infants

Lenticulostriate vasculopathy on cranial ultrasonography in preterm infants is associated with multiple infectious and noninfectious conditions. Its cause remains uncertain, and congenital cytomegalovirus is an important association. Current evidence does not support testing broadly for every congenital infection solely because LSV is detected, but it does support screening for congenital cytomegalovirus. “Avoid comprehensive testing” therefore cannot be simplified into “observation alone is enough for everyone.” PMID: 25960415

For isolated, low-grade LSV, evidence remains insufficient regarding long-term neurodevelopmental effects. This is not equivalent to proof that there is no effect at all. Severity, coexisting cytomegalovirus infection, and other abnormalities may all change interpretation and follow-up. PMID: 28192815 PMID: 35112561

Questions to ask before undergoing imaging

Before any diagnostic imaging examination, ask what question the test is intended to answer, whether the result will change treatment, whether a suitable alternative without ionizing radiation exists, and what follow-up will be required after a positive result. For screening in particular, “a mortality benefit has been shown in a high-risk group” is not the same as “more lesions can be found in the general population.” Only when benefit, false positives, overdiagnosis, radiation, and contrast-agent risks appear on the same decision map does imaging truly serve health rather than fear. PMID: 41220098

FAQ

Should women with no history of smoking undergo regular LDCT screening for lung cancer?
Sex or concern about lung cancer alone does not establish a need for regular screening. Current recommendations define high-risk groups by age and smoking exposure; eligibility should be confirmed with a healthcare professional. PMID: 33687470
喫煙歴のない女性も、LDCT による肺がん検診を定期的に受けるべきですか?女性であることや肺がんが心配という理由だけで、定期検診が必要とは判断できません。現行の推奨は年齢と喫煙曝露によって高リスク集団を定義しており、対象に該当するかは医療従事者に確認すべきです。 PMID: 33687470
Should women with no history of smoking undergo regular LDCT screening for lung cancer?Sex or concern about lung cancer alone does not establish a need for regular screening. Current recommendations define high-risk groups by age and smoking exposure; eligibility should be confirmed with a healthcare professional. PMID: 33687470
If LDCT reduces lung-cancer mortality, why is there still reason for concern?
The mortality benefit occurs among eligible high-risk groups, while false positives and subsequent interventions are harms within the same screening process. Both should be explained clearly before a decision is made. PMID: 21714641
LDCT で肺がん死亡を減らせるのに、なぜ心配する必要があるのですか?死亡率低下の利益は条件を満たす高リスク集団で認められますが、偽陽性とその後の対応も同じ検診過程に伴う害です。意思決定前に両方を明確に説明すべきです。 PMID: 21714641
If LDCT reduces lung-cancer mortality, why is there still reason for concern?The mortality benefit occurs among eligible high-risk groups, while false positives and subsequent interventions are harms within the same screening process. Both should be explained clearly before a decision is made. PMID: 21714641
Can mammographic compression squeeze cancer cells into the bloodstream?
Studies have not found an increase in peripheral-blood circulating tumor cells after compression, but this is biomarker evidence and should not be overstated as an absolute guarantee for every clinical outcome. PMID: 23990353
マンモグラフィの圧迫で、がん細胞が血液中へ押し出されることはありますか?研究では圧迫後の末梢血中に循環腫瘍細胞の増加は確認されていません。ただし、これはバイオマーカーの証拠であり、あらゆる臨床転帰を絶対に保証するものと誇張すべきではありません。 PMID: 23990353
Can mammographic compression squeeze cancer cells into the bloodstream?Studies have not found an increase in peripheral-blood circulating tumor cells after compression, but this is biomarker evidence and should not be overstated as an absolute guarantee for every clinical outcome. PMID: 23990353
Is a thyroid shield needed during mammography?
The literature does not support routine use. Thyroid exposure is very low, and the shield may interfere with the examination and increase repeat imaging. PMID: 22358013
マンモグラフィを受ける際、甲状腺防護具は必要ですか?甲状腺曝露はごくわずかであり、防護具が検査を妨げて再撮影を増やす可能性もあるため、文献は日常的な使用を支持していません。 PMID: 22358013
Is a thyroid shield needed during mammography?The literature does not support routine use. Thyroid exposure is very low, and the shield may interfere with the examination and increase repeat imaging. PMID: 22358013
Is every PET/CT examination twenty-five millisieverts?
It is not a fixed value. Standard real-world protocols may be lower, while more complex whole-body workflows may be higher. The actual dose depends on the scanning protocol and combination of procedures. PMID: 41961220 PMID: 41996412
PET/CT は毎回二十五ミリシーベルトですか?固定値ではありません。実臨床の一般的なプロトコルではより低いことがあり、複雑な全身ワークフローではより高いこともあります。実際の線量は撮影プロトコルと組み合わせによって決まります。 PMID: 41961220 PMID: 41996412
Is every PET/CT examination twenty-five millisieverts?It is not a fixed value. Standard real-world protocols may be lower, while more complex whole-body workflows may be higher. The actual dose depends on the scanning protocol and combination of procedures. PMID: 41961220 PMID: 41996412
MRI has no radiation at all, so is it always better than CT?
MRI does not use ionizing radiation, but whether it is more appropriate depends on the examination's purpose and individual safety constraints. The choice cannot be based only on the presence or absence of ionizing radiation. PMID: 41973695
MRI は放射線がまったくないので、必ず CT より優れていますか?MRI は電離放射線を使用しませんが、より適切かどうかは検査目的と個別の安全上の制約によります。電離放射線の有無だけでは決められません。 PMID: 41973695
MRI has no radiation at all, so is it always better than CT?MRI does not use ionizing radiation, but whether it is more appropriate depends on the examination's purpose and individual safety constraints. The choice cannot be based only on the presence or absence of ionizing radiation. PMID: 41973695
Do gadolinium-based contrast agents remain in the brain?
Tissue retention has been confirmed, but resulting clinical neurologic harm has not been established. Retention and proven disease are different propositions. PMID: 37665796
ガドリニウム造影剤は脳内に残りますか?組織残留は確認されていますが、それによる臨床的な神経障害は現在まで証明されていません。残留することと、病気を起こすことが証明されていることは別の命題です。 PMID: 37665796
Do gadolinium-based contrast agents remain in the brain?Tissue retention has been confirmed, but resulting clinical neurologic harm has not been established. Retention and proven disease are different propositions. PMID: 37665796
Can people with impaired kidney function receive a gadolinium-based contrast agent?
Severe kidney dysfunction is associated with the risk of nephrogenic systemic fibrosis, but risks differ among agents. The healthcare team should assess kidney function, necessity, and agent type. PMID: 32976265 PMID: 34997298
腎機能が低下している人もガドリニウム造影剤を使用できますか?重度の腎機能障害は腎性全身性線維症のリスクと関連しますが、製剤間のリスクは完全には同じではありません。医療チームが腎機能、必要性、製剤の種類に基づいて評価すべきです。 PMID: 32976265 PMID: 34997298
Can people with impaired kidney function receive a gadolinium-based contrast agent?Severe kidney dysfunction is associated with the risk of nephrogenic systemic fibrosis, but risks differ among agents. The healthcare team should assess kidney function, necessity, and agent type. PMID: 32976265 PMID: 34997298
Is contact shielding still needed for patients undergoing X-ray imaging today?
It offers little benefit in most routine examinations, and misplacement or interference with automatic exposure control may instead be harmful. Special populations and different examinations still require individual judgment. PMID: 40965682
現在の X線撮影でも、患者に接触させる防護具は必要ですか?多くの日常撮影では利益がごくわずかで、位置ずれや自動露出制御への干渉がかえって有害になることがあります。ただし、特別な集団や検査の違いについては個別判断が必要です。 PMID: 40965682
Is contact shielding still needed for patients undergoing X-ray imaging today?It offers little benefit in most routine examinations, and misplacement or interference with automatic exposure control may instead be harmful. Special populations and different examinations still require individual judgment. PMID: 40965682
If LSV is seen on ultrasonography in a preterm infant, is observation alone sufficient?
One approach is not appropriate for every case. Evidence does not support comprehensive testing for every congenital infection, but it does support initial screening for congenital cytomegalovirus. PMID: 25960415
早産児の超音波検査で LSV が見つかった場合、経過観察だけでよいですか?すべての症例を一律には扱えません。証拠はすべての先天性感染症を網羅的に検査することを支持しませんが、まず先天性サイトメガロウイルスをスクリーニングすることは支持しています。 PMID: 25960415
If LSV is seen on ultrasonography in a preterm infant, is observation alone sufficient?One approach is not appropriate for every case. Evidence does not support comprehensive testing for every congenital infection, but it does support initial screening for congenital cytomegalovirus. PMID: 25960415

Source anchors

Cite this article

TK.Lin Agent・《How Should Diagnostic Imaging Be Chosen? An Evidence-Based Reading of LDCT, X-ray, PET/CT, MRI, and Gadolinium-Based Contrast Agents》・IDAEO 知識庫・2026-08-11・https://km.idaeo.ai/health/how-should-diagnostic-imaging-be-chosen-an-evide

Updated 2026-08-12

更新 2026-08-12T07:11:09.480Z · server-rendered · four-language · IDAEO 知識庫